title: The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis.
abstract: OBJECTIVE
  This study examined the effects of secretory leukocyte protease inhibitor (SLPI), a protease inhibitor in tears, in allergic conjunctivitis.
  
  
  METHODS
  Conjunctiva of male Hartley guinea pigs sensitized with ovalbumin were treated with SLPI or the vehicle 10 min before antigen challenge or simultaneously. The animals were sacrificed after antigen challenges of 0-24 h duration, and the inhibition of eosinophil conjunctival migration and degranulation by SLPI was analyzed histochemically. The effects of SLPI on mast cell chymase and tryptase were also examined.
  
  
  RESULTS
  Treatment of sensitized guinea pigs with SLPI suppressed the conjunctival recruitment and degranulation of eosinophils after antigen challenge for 6 h, inhibiting the development of allergic conjunctivitis. The effects of SLPI were observed at concentrations > or =0.1 microM, with a peak at 5 microM. SLPI inhibited chymase in a dose-dependent manner, but had no effect on tryptase.
  
  
  CONCLUSIONS
  The topical SLPI application may be therapeutic in allergic conjunctivitis.
authors.affiliation: Department of Ophthalmology and Visual Neuroscience, School of Medicine, The University of Tokushima, Tokushima 770-8503, Japan.
authors.forename: Eiko
authors.initials: E
authors.lastname: Murata
authors.forename: Saimoon
authors.initials: S
authors.lastname: Sharmin
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiota
authors.forename: Mayumi
authors.initials: M
authors.lastname: Shiota
authors.forename: Mihiro
authors.initials: M
authors.lastname: Yano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kido
mesh_terms: D000287:Administration, Topical; D000818:Animals; D015550:Cell Degranulation; D002465:Cell Movement / Q000187:drug effects; D053818:Chymases; D003233:Conjunctivitis, Allergic / Q000473:pathology / Q000503:physiopathology*; D004804:Eosinophils / Q000187:drug effects* / Q000502:physiology*; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000187:drug effects / Q000201:enzymology; D009994:Osmolar Concentration; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000008:administration & dosage*; D053481:Secretory Leukocyte Peptidase Inhibitor; D012697:Serine Endopeptidases / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage*; D053802:Tryptases
chemical_list: D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D015842:Serine Proteinase Inhibitors; D012697:Serine Endopeptidases; D053818:Chymases; D053802:Tryptases